Postprandial hyperglycemia: are all sulfonylureas created equal?
Kapoor
John R
JR
D002219:Carbamates / Q000627:therapeutic use; D003510:Cyclohexanes / Q000627:therapeutic use; D005913:Glipizide / Q000627:therapeutic use; D006801:Humans; D006943:Hyperglycemia / Q000188:drug therapy* / Q000503:physiopathology; D006949:Hyperlipidemias / Q000188:drug therapy* / Q000503:physiopathology; D007004:Hypoglycemic Agents / Q000627:therapeutic use*; D000077715:Nateglinide; D010649:Phenylalanine / Q000031:analogs & derivatives / Q000627:therapeutic use; D010880:Piperidines / Q000627:therapeutic use; D019518:Postprandial Period / Q000502:physiology*; D013453:Sulfonylurea Compounds / Q000627:therapeutic use
D002219:Carbamates; D003510:Cyclohexanes; D007004:Hypoglycemic Agents; D010880:Piperidines; D013453:Sulfonylurea Compounds; D000077715:Nateglinide; D010649:Phenylalanine; C072379:repaglinide; C057619:glimepiride; D005913:Glipizide